
RFK Jr. wants to crack down on drug ads. That could cripple some broadcasters
While not an outright ban, the two policies would make it significantly more difficult and expensive for drug companies to push their products across broadcasters' airwaves, according to a Bloomberg report on Tuesday. The policies look to either mandate that advertisers elaborate on the risks posed by their drugs — forcing ads to be longer and, therefore, more expensive — or bar drugmakers from writing off direct-to-consumer ads as business expenses on their taxes, also padding the bill, Bloomberg reported.
Drug ads, which are illegal in most countries, have been a hallmark of US television since the 1980s. By raising the bar on pharmaceutical ads, the Trump administration threatens a crucial revenue source for broadcasters.
Drug companies spent $5.15 billion on TV ads in 2024, a significant figure considering a recent study found that drugmakers spent almost $14 billion on direct-to-consumer ads in 2023. Despite leaner audience numbers, linear television saw an uptick in pharmaceutical ad buys in 2024, which reached $3.4 billion during the first eight months of 2024, an 8.1% year-over-year increase.
Get Reliable Sources newsletter
Sign up here to receive Reliable Sources with Brian Stelter in your inbox.Almost 50% of those drug ads were split across news broadcasters, including MSNBC, CBS News, CNN and Fox News, according to a December report from research firm eMarketer.
Kennedy has long criticized the pharmaceutical industry's ability to directly advertise to consumers, which he argues leads to Americans' greater use of prescription medications. HHS acknowledged it is examining the issue but said no final decisions have been made.
'As Secretary Kennedy has consistently emphasized, direct-to-consumer pharmaceutical advertising must prioritize accuracy, patient safety, and the public interest — not profit margins,' HHS spokesperson Andrew Nixon said in a statement, adding that the department is 'exploring ways to restore more rigorous oversight and improve the quality of information presented to American consumers.'
The Pharmaceutical Research and Manufacturers of America, a main industry trade association known as PhRMA, did not return a request for comment.
The pair of policies would affect broadcasters airing entertainment and news alike. While news broadcasters' finances are buttressed by several sources of income — including ad revenue, licensing fees, cable and satellite fees and digital subscriptions — disincentivizing direct-to-consumer drug ads would harm traditional broadcasters and cable companies. News broadcasters have struggled for years as digital platforms, including social media platforms and streaming giants, have peeled away their ad income.
After Kennedy floated banning drug ads in November, Steve Tomsic, Fox Corporation's chief financial officer, told the UBS Global Media and Communications Conference that 'it would take an enormously draconian ban on it for it to really have an impact.'
'From a quantitative perspective, it's low, single-digit percentage of our overall revenue,' Tomsic said of Fox Corp's drug ads. Fox did not provide a comment for this story at the time of publication.
A CNN spokesperson emphasized the policies would be bad for the industry. Disney, ABC News and MSNBC did not respond when asked how the policies would affect their businesses. NBCUniversal, NBC News, Paramount, CBS News and Warner Bros. Discovery (CNN's parent company) declined to comment.
President Donald Trump has attempted to exert control over drug industry advertising in the past. During his first term, HHS issued a regulation that would have required drug makers to include their list prices in TV ads, but a federal judge nixed the effort, saying the agency had overstepped its authority. It was a centerpiece of Trump's efforts to lower drug prices at the time.
While cutting drug costs is not as high a priority this term, Trump has signed two executive orders that aim to target high drug prices. One of them called for HHS to explore facilitating pharmaceutical companies' ability to directly sell their drugs to patients at the 'most-favored-nation price,' which is tied to lower prices paid in other developed countries.
The Trump administration is not alone in targeting drug ads this term. Just last week, a group of legislators led by Senators Bernie Sanders, an independent from Vermont, and Angus King, an independent from Maine, introduced a bill that looked to ban drugmakers from promoting their products on direct-to-consumer channels. Instead of an outright ban, HHS' policies would strong-arm drug advertisers into submission, avoiding costly legal battles that would play out in the courts.
The US Food and Drug Administration established strict guidelines for TV drug ads in 1985, mandating that they include the drugs' side effects. It wasn't until 1997, when the FDA relaxed its policy, that the ads really took off. There is no cap on how many or how often broadcasters can run drug ads.
Drug stocks dipped following Bloomberg's Tuesday report, with Johnson & Johnson (JNJ) down 2.69 points, Pfizer (PFE) down 0.40 points and AstraZeneca (AZN) down 2.47 points at the time of publication.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
Why Applied Digital Stock Skyrocketed 31% Today
Key Points Applied Digital surged after CoreWeave expanded its AI computing lease, pushing the total contract value to $11 billion. The lease announcement prompted analysts at Citizens to raise APLD's price target, reflecting bullish near-term sentiment amid rising AI infrastructure demand. 10 stocks we like better than Applied Digital › Shares of Applied Digital (NASDAQ: APLD) jumped on Thursday, finishing the day up 31%. The huge spike came as the S&P 500 and Nasdaq Composite lost 0.4% and 0.1%, respectively. The Bitcoin miner-turned artificial intelligence (AI) cloud computing provider reported its second-quarter earnings. Despite somewhat mixed results, it was revealed that another major cloud provider intends to lease additional compute power. Applied Digital gets a big win Applied Digital announced that its partner CoreWeave exercised a lease option for an additional 150 MW of computing power, bringing the total contract value to $11 billion. This is the maximum the company can provide from its Ellendale, North Dakota, location. The analyst Greg Miller of Citizens maintained his buy rating on the stock after the news and raised his price target to $16. Big tech continues its AI spend The news comes as major AI players in big tech like Meta Platforms and Microsoft release their earnings results, showing no signs of reining in their AI capital expenditures (capex). Quite the opposite. Meta nearly doubled its capex year over year while Microsoft grew its capex by 22% to $17.1 billion and plans to increase that to $30 billion this quarter. That figure was 60% more than analysts expected. Applied is growing fast, but the future is uncertain While I think the company will continue to perform well in the near term, I have significant concerns about the business model long-term. The Metas and Microsofts of the world may be leaning on specialty cloud providers at the moment to keep up with the rapid growth of AI demand, but they are also heavily investing in building their own facilities. I don't see a strong moat for Applied Digital that makes me think this is a long-term hold. Should you buy stock in Applied Digital right now? Before you buy stock in Applied Digital, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Applied Digital wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $638,629!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,098,838!* Now, it's worth noting Stock Advisor's total average return is 1,049% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Johnny Rice has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Bitcoin, Meta Platforms, and Microsoft. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. Why Applied Digital Stock Skyrocketed 31% Today was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
8 minutes ago
- Yahoo
US Army pools contracts into up to $10 billion Palantir deal
(Reuters) -The U.S. Army on Thursday said it was consolidating dozens of contracts into a single enterprise deal with Palantir, giving it volume-based discounts and the option to purchase up to $10 billion from the software provider over 10 years. The deal does not commit the Army to any new purchases, it said in a press release. The Army said the goal of this consolidation was to shorten procurement timelines and remove contract-related fees so it can deploy data integration and artificial intelligence tools faster. (Reporting By Jeffrey Dastin in San Francisco; Editing by Chris Reese) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
8 minutes ago
- Yahoo
SPYD Attracts $759M in Assets as Fed Keeps Rates Unchanged
The SPDR Portfolio S&P 500 High Dividend ETF (SPYD) attracted $758.7 million Wednesday, bringing its assets under management to $7.8 billion, according to data provided by FactSet. The dividend-focused fund's inflows came as the S&P 500 slipped 0.1% after Federal Reserve Chair Jerome Powell indicated the central bank isn't ready to cut rates while assessing tariff impacts on inflation. Invest in Gold Thor Metals Group: Best Overall Gold IRA American Hartford Gold: #1 Precious Metals Dealer in the Nation Priority Gold: Up to $15k in Free Silver + Zero Account Fees on Qualifying Purchase The SPDR S&P 500 ETF Trust (SPY) pulled in $1.3 billion, while the Invesco QQQ Trust (QQQ) collected $1.1 billion as tech stocks helped lift the Nasdaq-100 0.2%. The Invesco Buyback Achievers ETF (PKW) gained $448.4 million, and the Schwab Short-Term US Treasury ETF (SCHO) attracted $420.6 million. The iShares Russell 2000 ETF (IWM) saw outflows of $935.1 million, while the Direxion Daily Semiconductor Bull 3x Shares (SOXL) lost $309.9 million. The iShares MSCI ACWI ETF (ACWI) experienced outflows of $445.8 million, and the Vanguard Intermediate-Term Corporate Bond ETF (VCIT) shed $546.8 million. U.S. equity ETFs attracted $5.1 billion for the day, while U.S. fixed-income funds gained $2.7 billion. Leveraged ETFs posted outflows of $356.4 million as Powell's comments poured cold water on September rate-cut expectations. Overall, ETFs collected $7.9 billion for the day. Track real-time ETF inflows and outflows for all tickers using ETF Fund Flows tool. Top 10 Creations (All ETFs) Ticker Name Net Flows ($, mm) AUM ($, mm) AUM % Change SPY SPDR S&P 500 ETF Trust 1,333.62 658,543.64 0.20% QQQ Invesco QQQ Trust Series I 1,077.58 362,236.15 0.30% SPYD SPDR Portfolio S&P 500 High Dividend ETF 758.67 7,755.06 9.78% VOO Vanguard S&P 500 ETF 476.20 713,260.09 0.07% PKW Invesco Buyback Achievers ETF 448.40 1,834.04 24.45% SCHO Schwab Short-Term US Treasury ETF 420.56 11,374.65 3.70% SCHR Schwab Intermediate-Term US Treasury ETF 383.46 11,376.81 3.37% LQD iShares iBoxx $ Investment Grade Corporate Bond ETF 317.35 27,139.06 1.17% MUB iShares National Muni Bond ETF 290.05 38,369.46 0.76% TLT iShares 20+ Year Treasury Bond ETF 279.36 48,808.63 0.57% Top 10 Redemptions (All ETFs) Ticker Name Net Flows ($, mm) AUM ($, mm) AUM % Change IWM iShares Russell 2000 ETF -935.08 63,674.80 -1.47% VCIT Vanguard Intermediate-Term Corporate Bond ETF -546.78 53,710.56 -1.02% ACWI iShares MSCI ACWI ETF -445.80 22,237.54 -2.00% SOXL Direxion Daily Semiconductor Bull 3x Shares -309.91 13,629.09 -2.27% EMXC iShares MSCI Emerging Markets ex China ETF -171.79 13,539.29 -1.27% MTUM iShares MSCI USA Momentum Factor ETF -168.48 17,521.89 -0.96% RSP Invesco S&P 500 Equal Weight ETF -139.85 73,780.01 -0.19% HYG iShares iBoxx $ High Yield Corporate Bond ETF -128.71 16,692.42 -0.77% TSLQ Tradr 2X Short TSLA Daily ETF Tradr 2X Short TSLA Daily ETF -126.62 395.08 -32.05% EMB iShares JP Morgan USD Emerging Markets Bond ETF -120.59 13,497.03 -0.89% ETF Daily Flows By Asset Class Net Flows ($, mm) AUM ($, mm) % of AUM Alternatives 14.93 10,482.90 0.14% Asset Allocation 46.13 25,919.79 0.18% Commodities ETFs -133.46 224,304.84 -0.06% Currency 368.51 181,502.17 0.20% International Equity 202.01 1,920,723.06 0.01% International Fixed Income -29.86 310,599.20 -0.01% Inverse -44.04 14,461.90 -0.30% Leveraged -356.36 149,239.85 -0.24% US Equity 5,103.25 7,357,474.53 0.07% US Fixed Income 2,720.42 1,722,374.22 0.16% Total: 7,891.51 11,917,082.46 0.07% Disclaimer: All data as of 6 a.m. Eastern time the date the article is published. Data are believed to be accurate; however, transient market data are often subject to subsequent revision and correction by the | © Copyright 2025 All rights reserved Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data